Roivant Sciences Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Matthew Gline
- Full Time Employees
- 721
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 50 Broadway London GL United Kingdom SW1H 0DB
- IPO Date
- Dec 8, 2020
- CIK
- 0001635088
- Website
- roivant.com
- Similar Companies
- Business
- Roivant Sciences Ltd. Roivant Sciences Ltd. (ROIV) is a biopharmaceutical company that accelerates the discovery, development, and commercialization of transformative medicines and technologies by creating nimble, autonomous subsidiaries known as Vants; these entities focus on specific drug candidates and therapeutic areas, leveraging centralized resources, proprietary computational platforms, and aligned incentives to enhance efficiency across diverse disease categories including autoimmune disorders, inflammatory conditions, pulmonary diseases, rare genetic disorders, and women's health. The company offers an extensive pipeline of investigational products and services, encompassing small molecule inhibitors such as brepocitinib, a dual TYK2/JAK1 inhibitor developed by Priovant for dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases; monoclonal antibodies including batoclimab and IMVT-1402 from Immunovant, which target the neonatal Fc receptor (FcRn) to reduce IgG levels in autoimmune indications like generalized myasthenia gravis, Graves' disease, Sjögren’s disease, and thyroid eye disease; inhaled therapies like mosliciguat, an sGC activator advanced by Pulmovant for pulmonary hypertension associated with interstitial lung disease (PH-ILD); nucleic acid delivery platforms through Genevant for RNA and gene therapies; and additional modalities such as topical aryl hydrocarbon receptor agonists like VTAMA (tapinarof) cream for plaque psoriasis and atopic dermatitis, previously commercialized via Dermavant; Roivant also provides healthcare technologies via units like Datavant for secure data linkage and Lokavant for clinical trial optimization. Roivant Sciences Ltd. operates globally with major offices in New York City and Boston in the United States, Basel in Switzerland, and London in the United Kingdom; founded in 2014 by Vivek Ramaswamy and now led by CEO Matt Gline, the company targets patient populations across immunology, pulmonology, neurology, oncology, and rare diseases through its decentralized Vant model, which supports over a dozen subsidiaries and has delivered 12 positive Phase 3 trials since 2019 along with multiple FDA approvals. Recent major developments include the 2024 sale of Dermavant Sciences to Organon for up to $1.2 billion, encompassing VTAMA and expanding commercial capabilities in immuno-dermatology; the creation of Pulmovant in 2024 following an exclusive worldwide license for mosliciguat from Bayer AG for $14 million upfront plus up to $280 million in milestones and royalties; positive Phase 3 VALOR trial results in 2025 for brepocitinib in dermatomyositis, with plans for a new drug application in early 2026 and ongoing Phase 3 studies in non-infectious uveitis; Phase 3 success for batoclimab in myasthenia gravis alongside prioritization of next-generation IMVT-1402 with data expected in 2027; a $1 billion collaboration in 2025 with VantAI and Halda Therapeutics to develop AI-generated RIPTAC molecular glues using the Neo-1 platform for autoimmune and pulmonary diseases; increased stake in Immunovant through a $336.9 million share purchase in early 2025; orphan drug designation in Japan for mosliciguat; and Phase 1b ATMOS study data demonstrating significant reductions in pulmonary vascular resistance for PH-ILD, positioning Roivant for multiple near-term catalysts including potential blockbuster launches in immunology and pulmonology.
Company News
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells $196,236.12 in Stock
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants
Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Roivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript
Stock Futures Mixed to Start Holiday-Shortened Week
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate
Roivant's experimental lung disease drug meets goals in mid-stage study
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month
US FDA approves Roivant-Priovant's skin and muscle disease drug